The Danish pharmaceutical company behind Ozempic and Wegovy rode the GLP-1 weight-loss drug wave to become Europe's most valuable company with returns exceeding 700%, outpacing #1 Costco's growth by over 500% in the same timeframe. This rapid rise delivered 28% average annual returns, nearly double the typical pharma sector benchmark of 15%.
Comments on "Novo Nordisk (NVO)"
Create a free account or sign in to join the discussion.
Sign in to join the conversation